Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis

Objectives: To determine the efficacy of oral theophylline compared with placebo in people with stable chronic obstructive pulmonary disease (COPD).Methods: Systematic review of randomized-controlled trials comparing oral Theophylline; with placebo for a minimum of 7 days in people with stable COPD....

ver descrição completa

Detalhes bibliográficos
Autores: Ram, Felix SF, Jardim, José Roberto, Atallah, Álvaro Nagib [UNIFESP], Castro, Aldemar Araujo [UNIFESP], Mazzini, Renato Coimbra [UNIFESP], Goldstein, Roger, Lacasse, Yves, Cendon Filha, Sônia Perez [UNIFESP]
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2005
País:Brasil
Recursos:Universidade Federal de São Paulo (UNIFESP)
Repositorio:Repositório Institucional da UNIFESP
Idioma:inglés
OAI Identifier:oai:repositorio.unifesp.br:11600/28120
Acesso em linha:http://dx.doi.org/10.1016/j.rmed.2004.10.009
http://repositorio.unifesp.br/handle/11600/28120
Access Level:acceso abierto
Palavra-chave:COPD
oral
theophylline
systematic review
meta-analysis
cochrane
Descrição
Resumo:Objectives: To determine the efficacy of oral theophylline compared with placebo in people with stable chronic obstructive pulmonary disease (COPD).Methods: Systematic review of randomized-controlled trials comparing oral Theophylline; with placebo for a minimum of 7 days in people with stable COPD.Results: Twenty randomized-controlled trials were included in this review. the Meta-analysis; following outcomes showed significant improvement with theophylline compared with placebo: FEV, and FVC both improved with theophylline (weighted mean difference [WMD] 0.10 L; 95% confidence interval [95% CI] 0.04-0.16 and WMD 0.21 L; 95% CI 0.10-0.32, respectively). VO2 max also improved with theophylline (WMD 195.27mL/ min; 95% Cl 112.71-277.83), as did PaO2 and PaCO2 (WMD 3.18mmHg;,95% Cl 1.23-5.13 and WMD -2.36mmHg; 95% Cl -3.52 to -1.21, respectively). Patients preferred theophylline over placebo (relative risk 2.27; 95% Cl 1.26-4.11). Theophylline increased the risk of nausea compared with placebo (RR 7.67; 95% Cl 1.47-39.94).Conclusion: This review has shown that theophylline still has a role in the management of stable COPD, and is preferred by patients over placebo. However, the benefits of theophylline in stable COPD have to be weighed against the risk of adverse effects. (C) 2004 Elsevier B.V. All rights reserved.